On Thursday, March 7, AcelRx (NASDAQ: ACRX) reported its 2018 financial results, presenting a strong picture overall. With a large cash balance and controlled burn rate, AcelRx is in an excellent position to build a market share for Dsuvia and demonstrate the sustainability of the company's business model. Management's comments on the company's last earnings call also indicate that the market may be quite eager to adopt Dsuvia. Though at this point investors can only wait until the company releases Q1 2019 results to see how Dsuvia's launch has performed from a revenue